Clinical Study

Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria

Table 3

Unadjusted analysis comparing cases with resistance to isoniazid alone, rifampicin alone, both (MDR-TB), and those with any resistance to those without any drug resistance among participants receiving care at two TB treatment sites in northern Nigeria.

CharacteristicsIsoniazid resistance onlyRifampicin resistance onlyMDR-TB resistanceANY resistanceNO resistance
(%)Odds ratio,
95% CI
value (%)Odds ratio,
95% CI
value (%)Odds ratio,
95% CI
value (%)Odds ratio,
95% CI
value Reference category

HIV infection7 (53.9)3.44, 1.12–10.530.0473 (60.0)4.35, 0.71–26.900.1102 (40.0)2.01, 0.33–12.020.60512 (52.2)3.22, 1.40–7.630.00889 (25.3)
Prior TB treatment5 (38.5)4.45, 1.38–14.260.0181 (20.0)1.79, 0.18–16.360.4852 (40.0)4.71, 0.82–29.440.1228 (34.8)3.81, 1.49–9.450.00843 (12.2)
Majority Hausa-Fulani
ethnic group
13 (100)0.0444 (80.0)1.32, 0.12–11.731.0001 (20.0)0.14, 0.01–0.720.01618 (78.3)1.20, 0.41–3.201.000266 (75.6)
Female sex2 (15.4)1.19, 0.41–3.870.7682 (40.0)1.30, 0.21–8.021.0001 (20.0) 0.41, 0.13–4.520.6698 (34.8)1.13, 0.36–2.621.000118 (33.5)
Site A (Zaria)12 (92.3)2.29, 0.32–18.230.7013 (60.0)0.33, 0.01–1.780.1925 (100)1.0020 (86.7)1.35, 0.43–4.491.000295 (83.8)
Alcohol consumption0 (0.0)0.1371 (20.0)1.22, 0.11–10.761.0003 (60.0)7.10, 1.19–43.550.0424 (17.4)1.00, 0.30–3.011.00061 (17.3)
Diabetes mellitus1 (7.7)1.84, 0.22–14.490.4620 (0.0)1.0002 (40.0)15.89, 2.51–102.900.0183 (13.0)3.59, 0.91–13.530.07914 (4.0)
Cigarette smoking2 (15.4)0.52, 0.14–2.220.5273 (60.0)3.88, 0.61–24.030.1363 (60.0)3.92, 0.61–24.000.1368 (34.8)1.41, 0.60–3.420.47597 (27.6)

MDR-TB: multidrug resistant tuberculosis (resistance to both isoniazid and rifampicin).
ANY resistance: Resistance to isoniazid, rifampicin, or both; NO resistance: not resistant to either isoniazid or rifampicin.
*Odds ratio estimation not possible due to zero frequency cells.